Evrysdi
E561095
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Evrysdi canonical | 2 |
| risdiplam (Evrysdi) | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6004771 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Evrysdi Context triple: [risdiplam, hasBrandName, Evrysdi]
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Evrysdi Target entity description: Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
orphan drug ⓘ pharmaceutical drug ⓘ prescription medicine ⓘ |
| affectsBiologicalProcess | RNA splicing ⓘ |
| affectsProtein | survival motor neuron protein ⓘ |
| belongsToTherapeuticArea |
neurology
ⓘ
rare diseases ⓘ |
| hasActiveIngredient | risdiplam ⓘ |
| hasApprovalYear | 2020 ⓘ |
| hasATCCode | M09AX10 ⓘ |
| hasBlackBoxWarning | none ⓘ |
| hasCommonAdverseEffect |
arthralgia
ⓘ
diarrhea ⓘ fever ⓘ headache ⓘ nausea ⓘ rash ⓘ ulceration of the mouth ⓘ upper respiratory tract infection ⓘ urinary tract infection ⓘ |
| hasDeveloper |
Genentech
ⓘ
PTC Therapeutics ⓘ Roche ⓘ SMA Foundation ⓘ |
| hasDosingBasis | patient body weight ⓘ |
| hasDosingPopulation |
adults
ⓘ
children ⓘ infants ⓘ |
| hasGenericName | risdiplam ⓘ |
| hasIndication | treatment of spinal muscular atrophy in patients 2 months of age and older ⓘ |
| hasManufacturer | Genentech ⓘ |
| hasMechanismOfAction |
SMN2 pre-mRNA splicing modifier
ⓘ
increases production of functional SMN protein ⓘ |
| hasPregnancyCategory | can cause fetal harm based on animal data ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStorageCondition |
refrigerate before reconstitution
ⓘ
store at room temperature after reconstitution for limited time ⓘ |
| hasTradeNameOwner | Genentech ⓘ |
| isAdministered |
by mouth
ⓘ
once daily ⓘ |
| isApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| isDosageForm | oral solution ⓘ |
| isFirstInClass | first oral SMN2 splicing modifier approved for SMA ⓘ |
| isTakenWith | food or liquid ⓘ |
| isUsedIn | long-term treatment of spinal muscular atrophy ⓘ |
| targets | SMN2 pre-mRNA ⓘ |
| treats |
5q-associated spinal muscular atrophy
ⓘ
spinal muscular atrophy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Evrysdi Description of subject: Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Evrysdi